Novartis Avidity Drug Fails in Third Trial Setback in a Week

Novartis Avidity Drug Fails in Third Trial Setback in a Week

Novartis suffered its third clinical-trial setback in a week after del-desiran, a treatment for a rare muscle-wasting disease, failed a late-stage study.

Novartis Suffers Third Drug Trial Setback in a Week

Novartis has suffered its third clinical trial setback in a week after its drug del-desiran failed a late-stage study in muscle disorder patients. This is a significant blow for the company. Del-desiran was central to Novartis’s 12 billion dollar acquisition of Avidity Biosciences and had been viewed internally as a...

Novartis (NVS) Stock Plunges 12% as Del-Desiran Trial Flops in Brutal Week

Novartis (NVS) stock crashed 12% after del-desiran failed Phase III HARBOR trial, the third drug setback this week for the pharmaceutical company.

Novartis (NVS) Stock Craters 12% After Three Drug Failures in One Week

TLDR Novartis fell over 12% on Tuesday, on track for its worst trading day since March 2020. Its del-desiran drug failed the Phase III HARBOR trial for myotonic dystrophy type 1, missing the primary endpoint. This marks the third drug trial setback for Novartis in a week, following the pelacarsen...